Study the Effect of Ciprofloxacin and Diclofenac Combination Treating Urinary Tract Infection by Resistance Ecoli 0157H7 in Female Rabbits
Study the Effect of Ciprofloxacin and Diclofenac Combination Treating Urinary Tract Infection by Resistance Ecoli 0157H7 in Female Rabbits
Frah R Kbyeh1*, Ahmed N. Abedsalih2
ABSTRACT
This study is designed to highlight some of the anti-bacterial effect for diclofenac aganist resist. E .coli 0157: H7, as well as the ability of the diclofenac represented by anti-inflammatory and ciprofloxacin combat the exposure of urinary tract infection. The virulence components responsible for colonization and penetration also have a role in the pathogenicity of the resistant Escherichia coli 0157: H7 strain. Resistance Escherichia coli 0157 H7 for antibiotics decreases the cure rate. Repurposing Food and Drug Administration (FDA) approved medications against the contributing factors is a novel method to overcome this scarcity. The analgesic medication diclofenac was reported to have anti-virulence action against resistance Escherichia coli O157 :H7. This study aimed to demonstrate the antimicrobial effect of diclofenac, Ciprofloxacin, and a combination (diclofenac +ciprofloxacin) against clinical resistance E coli o157 H7 isolates by using Polymerase chain reaction (PCR). The presented study, all rabbits, forty-eighth adult female rabbit aged (6-8 weeks) and weighing between (1500 and 2000) gm., was randomly divided into six equal groups(8/each) groups injection 0.1 ml in 1 x 109 CFU Escherichia coli 0157: H7 by urinary catheterization route excepting in negative control and all groups resulted in a significant increase in urea creatinine, sodium, Potassium, chloride concentration in the blood after three days comparison with negative control and in all experimental period (14 days) which was no significant change (P < 0.05) between positive control (PC) and diclofenac treated groups but combination (ciprofloxacin 3.5 mg/kg+diclofenac1mg/kg) COM1 group and combination (ciprofloxacin 1.75 mg/kg+diclofenac1mg/kg) com2 significant decrease (P< 0.05) after (seven, fourteen) days comparison with positive control ,diclofenac group was used in combination with antibiotics as the anti-virulence agent which was enhance the ability of the immune system to eradicate infection. Altogether, we can conclude that the diclofenac has the required anti-boiflim effects to support ciprofloxacin effect and the body responses against urinary tract infection consequences of E coli O157 :H7
To share on other social networks, click on any share button. What are these?
